Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

SABCS 2019

10 - 14 Dec 2019
Henry B. Gonzalez Convention Center, San Antonio, United States of America
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-pos...
Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer ( Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA )
23 Jan 2020
Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast c...
Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras
Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast cancer ( Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras )
23 Jan 2020
Selective oestrogen receptor degraders as treatment for ER positive/HER2 negativ...
Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium
Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer ( Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium )
19 Dec 2019
The challenges of treating breast cancer in Brazil
Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
The challenges of treating breast cancer in Brazil ( Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil )
19 Dec 2019
The importance of central pathology pCR review in an international multicenter n...
Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany
The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC ( Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany )
19 Dec 2019
SABCS 2019 highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
SABCS 2019 highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
19 Dec 2019
The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- ...
Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain
The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer ( Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain )
19 Dec 2019
Imaging for women who are high risk of breast cancer
Dr Maxine Jochelson - Memorial Sloan Kettering Cancer Center, New York City, USA
Imaging for women who are high risk of breast cancer ( Dr Maxine Jochelson - Memorial Sloan Kettering Cancer Center, New York City, USA )
19 Dec 2019
Adding S-1 to post-operative endocrine therapy in patients with hormone receptor...
Prof Masakazu Toi - Kyoto University, Kyoto, Japan
Adding S-1 to post-operative endocrine therapy in patients with hormone receptor-positive HER2-negative breast cancer ( Prof Masakazu Toi - Kyoto University, Kyoto, Japan )
19 Dec 2019
Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women ...
Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA
Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer ( Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA )
19 Dec 2019
KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant...
Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA
KEYNOTE-522: Neoadjuvant pembro   chemo vs placebo   chemo, followed by adjuvant pembro vs placebo for early TNBC ( Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA )
19 Dec 2019
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes...
Prof William Symmans - MD Anderson Cancer Center, Houston, Texas
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )
19 Dec 2019
Implementation of genetic testing in breast cancer patients
Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA
Implementation of genetic testing in breast cancer patients ( Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA )
19 Dec 2019
Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germli...
Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA
Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC ( Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA )
19 Dec 2019
Breast cancer screening and treatment in Brazil
Dr Gustavo Werutsky - Latin American Cooperative Oncology Group, Porto Alegre, B...
Breast cancer screening and treatment in Brazil ( Dr Gustavo Werutsky - Latin American Cooperative Oncology Group, Porto Alegre, Brazil )
19 Dec 2019
Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive b...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
19 Dec 2019
Long-term influence of oestrogen plus progestin vs oestrogen alone on breast can...
Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA
Long-term influence of oestrogen plus progestin vs oestrogen alone on breast cancer incidence in post-menopausal women ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )
19 Dec 2019
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes...
Prof William Symmans - MD Anderson Cancer Center, Houston, Texas
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )
19 Dec 2019
Circulating tumour DNA used to predict disease recurrence for early triple-negat...
Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indi...
Circulating tumour DNA used to predict disease recurrence for early triple-negative breast cancer ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )
19 Dec 2019
Oral paclitaxel with encequidar in metastatic breast cancer
Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras
Oral paclitaxel with encequidar in metastatic breast cancer ( Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras )
19 Dec 2019
Pathologic complete response rates improved with the neoadjuvant and adjuvant tr...
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembrolizumab in TNBC patients ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
18 Dec 2019
Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic c...
Dr Luca Gianni - San Raffaele Hospital, Milan, Italy
Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients ( Dr Luca Gianni -  San Raffaele Hospital, Milan, Italy )
18 Dec 2019
Breast cancer prevention in high-risk post-menopausal women
Prof Jack Cuzick - Queen Mary University of London, London, UK
Breast cancer prevention in high-risk post-menopausal women ( Prof Jack Cuzick - Queen Mary University of London, London, UK )
18 Dec 2019
Accelerated partial breast irradiation versus whole breast irradiation in patien...
Dr Icro Meattini - Univerity of Florence, Florence, Italy
Accelerated partial breast irradiation versus whole breast irradiation in patients with early breast cancer ( Dr Icro Meattini - Univerity of Florence, Florence, Italy )
18 Dec 2019
Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the...
Dr Luca Gianni - San Raffaele Hospital, Milan, Italy
Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer ( Dr Luca Gianni -  San Raffaele Hospital, Milan, Italy )
18 Dec 2019
Preventative effects of anastrozole in post-menopausal women who are at high-ris...
Prof Jack Cuzick - Queen Mary University of London, London, UK
Preventative effects of anastrozole in post-menopausal women who are at high-risk for developing breast cancer ( Prof Jack Cuzick - Queen Mary University of London, London, UK )
18 Dec 2019
How effective is accelerated partial breast irradiation in patients with early b...
Dr Icro Meattini - Univerity of Florence, Florence, Italy
How effective is accelerated partial breast irradiation in patients with early breast cancer? ( Dr Icro Meattini - Univerity of Florence, Florence, Italy )
18 Dec 2019
Predicting disease recurrence in patients with early triple-negative breast canc...
Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indi...
Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )
18 Dec 2019
The emerging role of immunotherapy for the treatment of early and advanced breas...
Dr Rita Nanda - UChicago Medicine, Chicago, USA
The emerging role of immunotherapy for the treatment of early and advanced breast cancer ( Dr Rita Nanda - UChicago Medicine, Chicago, USA )
18 Dec 2019
APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with op...
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )
18 Dec 2019
Breast cancer incidence in post-menopausal women: Long-term influence of oestrog...
Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA
Breast cancer incidence in post-menopausal women: Long-term influence of oestrogen plus progestin versus oestrogen alone ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )
18 Dec 2019
Could trastuzumab deruxtecan become the new standard of care for pretreated HER2...
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )
18 Dec 2019
Addition of S-1 to post-operative endocrine therapy for patients with hormone re...
Prof Masakazu Toi - Kyoto University, Kyoto, Japan
Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer ( Prof Masakazu Toi - Kyoto University, Kyoto, Japan )
18 Dec 2019
Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-p...
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )
18 Dec 2019
Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer p...
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1 ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )
18 Dec 2019
KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple...
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
18 Dec 2019